Home Industry News Skanska Signs $43MM Contract for Tenant Improvements with Juno Therapeutics in Seattle’s...

Skanska Signs $43MM Contract for Tenant Improvements with Juno Therapeutics in Seattle’s South Lake Union

Juno Therapeutic's Headquarters Building

Skanska, one of the world’s leading construction and development firms, announced it has signed a $43 million contract with Juno Therapeutics to complete a seven-floor, 155,000-SF tenant improvement at the company’s new South Lake Union headquarters at 400 Dexter Ave.

Skanska USA Building will include the full value of the contract in its third quarter 2016 order bookings. The architect is Flad Architects, and construction is already under way with completion scheduled for June 2017.

About Skanska
Skanska is one of the world’s leading project development and construction groups with expertise in construction, development of commercial and residential premises, and public-private partnerships projects. Based on its global green experience, Skanska aims to be the clients’ first choice for Green solutions. The Group currently has 43,100 employees in selected home markets in Europe and North America. Skanska’s sales in 2015 totaled SEK 155 billion.

About Juno Therapeutics
Juno is focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human T cells as therapeutics will drive one of the next important phases in medicine, we are developing cell-based cancer immunotherapies based on our chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. We have shown compelling evidence of tumor shrinkage in clinical trials using multiple cell-based product candidates to address refractory B-cell lymphomas and leukemias. Longer term, Juno aims to develop our cell-based platform to include additional product candidates to address a broad range of cancers and human diseases.